Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib in Relapsed/Refractory PCNSL or IOL
NCT02542514Phase 2Completed
- Sponsor
- LYSARC
- Start
- Sep 2015
- Primary completion
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ibrutinib in primary central nervous system lymphoma (PCNSL) and intraocular lymphoma, sponsored by LYSARC. Primary endpoint: Disease Control Rate (CR + CRu + PR + SD) at 2 months. Started Sep 2015; status: completed.
02
Drugs
ibrutinib
03
Conditions
primary central nervous system lymphoma (PCNSL)intraocular lymphoma
Beyond the preview
Go deeper on NCT02542514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02542514.